KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EPS (Weighted Average and Diluted) (2016 - 2025)

West Pharmaceutical Services' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $1.82 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 2.25% year-over-year to $1.82; the TTM value through Dec 2025 reached $6.79, up 1.49%, while the annual FY2025 figure was $6.79, 1.49% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.82 at West Pharmaceutical Services, down from $1.92 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.48 in Q2 2022 and bottomed at $1.23 in Q1 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is $1.85 (2023), against an average of $1.89.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 111.93% in 2021 before it crashed 31.17% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.89 in 2021, then dropped by 27.51% to $1.37 in 2022, then soared by 33.58% to $1.83 in 2023, then decreased by 2.73% to $1.78 in 2024, then increased by 2.25% to $1.82 in 2025.
  • Per Business Quant, the three most recent readings for WST's EPS (Weighted Average and Diluted) are $1.82 (Q4 2025), $1.92 (Q3 2025), and $1.82 (Q2 2025).